Efficacy and Safety of Olezarsen for the Management of Dyslipidemia: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
- 24 March 2026
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 269, 71-82
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and safety of Olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trialsDiscover Medicine, 2025
- APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemiaJournal of Clinical Lipidology, 2023
- Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2021
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular RiskJAMA, 2020
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeNew England Journal of Medicine, 2019
- Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVDCurrent Atherosclerosis Reports, 2019
- Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular DiseaseNew England Journal of Medicine, 2014
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemiaJournal of Lipid Research, 2001